Probiotic supplement for breathlessness and lung function in people with COPD
Tests a probiotic supplement against placebo in adults with chronic obstructive pulmonary disease.
Plain-language title generated from the registry record
Registry title: Probiotics in COPD: Effects on Symptoms, Lung Function, and Inflammation
Key facts
- Where
- Karlovac, Šibenik, Split, Vinkovci, and Zagreb, CroatiaSee the 5 sites
Where in Croatia
- General Hospital KarlovacKarlovac, CroatiaNo longer taking part
- General Hospital SibenikŠibenik, CroatiaNo longer taking part
- University Hospital SplitSplit, CroatiaNo longer taking part
- General Hospital VinkovciVinkovci, CroatiaNo longer taking part
- University Hospital Centre "Sestre Milosrdnice"Zagreb, CroatiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital of Split
- Trial code
- NCT07339280
- Record updated
- 21 April 2026
- Original description
The goal of this randomized, placebo controlled, double-blind clinical trial is to find out whether a probiotic supplement can help adults with chronic obstructive pulmonary disease (COPD) breathe better and better control their symptoms. The study will try to answer does taking a probiotic supplement, compare with a placebo, reduce shortness of breath, does it improve daily COPD symptoms or change stool patterns by using validated questionnaires; does it affect lung function or inflammation. The results of this study may contribute to a better understanding of the disease, the application of new therapeutic options, and provide a foundation for future research.Read full original descriptionShow less
"The Effect of Probiotics on the Degree of Dyspnea, Lung Function, and Inflammatory Mediators in Patients With Chronic Obstructive Pulmonary Disease (COPD)."
The goal of this randomized, placebo controlled, double-blind clinical trial is to find out whether a probiotic supplement can help adults with chronic obstructive pulmonary disease (COPD) breathe better and better control their symptoms. The study will try to answer does taking a probiotic supplement, compare with a placebo, reduce shortness of breath, does it improve daily COPD symptoms or change stool patterns by using validated questionnaires; does it affect lung function or inflammation. The results of this study may contribute to a better understanding of the disease, the application of new therapeutic options, and provide a foundation for future research.
Inclusion: Patients with a previously established diagnosis of COPD, regardless of the degree of airflow obstruction on pulmonary function testing; Age over 18 years, regardless of sex; Stable disease without exacerbations during the past two months (8 weeks); Stable disease without changes to maintenance therapy during the past two months (8 weeks); Patients with an mMRC score of 1 or higher; Signed informed consent.
Exclusion: patients on long-term systemic corticosteroid and immunosuppressive therapy (oral or intravenous form) as well as antifungal therapy,; patients who have recently participated in other clinical trials or have received experimental therapy,; patients with active alcoholism or drug addiction,; patients who have recently undergone surgery,; patients who have taken any probiotic preparations within one month before the start of the study,; patients diagnosed with serious comorbidities such as severe cardiovascular diseases (severe heart failure, acute coronary syndrome, or percutaneous coronary intervention within 6 months, uncontrolled tachy/bradyarrhythmias), patients with severe renal failure and a placed central venous catheter, patients with severe liver damage (Child-Pugh class C), patients with infectious hepatitis or HIV, active bloody diarrhea; patients who have had a stroke within the past 3 months; patients who have had a COPD exacerbation within the past two months and are not in a stable condition,; patients with a history of lung surgery or serious respiratory diseases other than COPD (active tuberculosis, sarcoidosis, pulmonary fibrosis, severe bronchiectasis, pulmonary aspergillosis, etc.),; patients with a history of severe allergic reactions or hypersensitivity to the components of the probiotic preparation,; patients with severe psychiatric diagnoses or those with significant physical or cognitive limitations that would interfere with following the study protocol,; patients undergoing active oncological and hematological treatment; transplanted patients, including allograft recipients; patients diagnosed with asthma,; pregnant or breastfeeding women,; patients whose COPD treatment is changed during the course of the study.